The switch from chemotherapy to hormone treatments for prostate cancer
BBC - 06-May-2020A safer and more immune-friendly precision-medicine approach for cancer
Join the club for FREE to access the whole archive and other member benefits.
Professor of Clinical Oncology specialising in urological cancer.
Professor James is Consultant in Clinical Oncology at the Queen Elizabeth Hospital Birmingham and Professor of Clinical Oncology at the University of Birmingham.
Professor James is internationally renowned for his work in Urological Cancer, particularly on the groundbreaking STAMPEDE trial, which has been used to evaluate, to date, 10 different therapies for advanced prostate cancer in more than 10,000 men. He is a regular educational speaker at conferences worldwide, recently including the American Society of Clinical Oncology, European Society of Medical Oncology and European Association of Urologists Annual Meetings. Results from STAMPEDE with both first line docetaxel chemotherapy and abiraterone have shown that big survival gains can be made by using existing treatments in novel settings. These findings have been practice changing worldwide.
Visit website: https://www.birmingham.ac.uk/staff/profiles/cancer-genomic/james-nicholas.aspx
See also: University of Birmingham - Public research university located in Edgbaston, United Kingdom
Details last updated 25-Oct-2019
A safer and more immune-friendly precision-medicine approach for cancer
Olaparib delays cancer growth by months, which means the increased lifespan
Overall, patients who received the drug lived 10 months longer, but for patients where the cancer...